{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T00:29:15Z","timestamp":1794702555401,"version":"4.9.1"},"reference-count":140,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.xcrm.2026.103058","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:02:09Z","timestamp":1790089329000},"page":"103058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic oligonucleotides as genetic medicines: The current state and future perspective"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6192-3333","authenticated-orcid":false,"given":"Bruno Miguel Da Cruz","family":"Godinho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal M.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1565-654X","authenticated-orcid":false,"given":"Annemieke","family":"Aartsma-Rus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.103058_bib1","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","article-title":"Therapeutic Antisense Oligonucleotides Are Coming of Age","volume":"70","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.xcrm.2026.103058_bib139","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2026.103058_bib3","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ymthe.2020.12.022","article-title":"Clinical Applications of Single-Stranded Oligonucleotides: Current Landscape of Approved and In-Development Therapeutics","volume":"29","author":"Scharner","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.103058_bib4","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1261\/rna.653607","article-title":"Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications","volume":"13","author":"Aartsma-Rus","year":"2007","journal-title":"RNA"},{"key":"10.1016\/j.xcrm.2026.103058_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2026.102938","article-title":"Argonaute and small RNAs in the nucleus: Mediators of gene silencing and activation","volume":"37","author":"Shcherbinina","year":"2026","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.xcrm.2026.103058_bib6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12943-021-01338-2","article-title":"RNA-based therapies: A cog in the wheel of lung cancer defense","volume":"20","author":"Khan","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.xcrm.2026.103058_bib7","series-title":"Advances in Nucleic Acid Therapeutics","article-title":"Conjugate-mediated Delivery of RNAi-based Therapeutics: Enhancing Pharmacokinetics\u2013Pharmacodynamics Relationships of Medicinal Oligonucleotides","author":"Godinho","year":"2019"},{"key":"10.1016\/j.xcrm.2026.103058_bib8","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1093\/nar\/gky037","article-title":"Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo","volume":"46","author":"Hassler","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib9","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1089\/nat.2014.0506","article-title":"Phosphorothioates, essential components of therapeutic oligonucleotides","volume":"24","author":"Eckstein","year":"2014","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.xcrm.2026.103058_bib10","doi-asserted-by":"crossref","first-page":"12483","DOI":"10.1021\/bi026225z","article-title":"Stereodefined Phosphorothioate Analogues of DNA: Relative Thermodynamic Stability of the Model PS-DNA\/DNA and PS-DNA\/RNA Complexes","volume":"41","author":"Boczkowska","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.xcrm.2026.103058_bib11","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1093\/nar\/23.24.5000","article-title":"Stereodifferentiation\u2014the effect of P chirality of oligo (nucleoside phosphorothioates) on the activity of bacterial RNase H","volume":"23","author":"Koziolkiewicz","year":"1995","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib12","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/oli.1.1997.7.567","article-title":"Stereodependent Inhibition of Plasminogen Activator Inhibitor Type 1 by Phosphorothioate Oligonucleotides: Proof of Sequence Specificity in Cell Culture and In Vivo Rat Experiments","volume":"7","author":"STEC","year":"1997","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"10.1016\/j.xcrm.2026.103058_bib13","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nbt.3948","article-title":"Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides","volume":"35","author":"Iwamoto","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.103058_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102246","article-title":"Preclinical evaluation of stereopure antisense oligonucleotides for allele-selective lowering of mutant <em>HTT<\/em>","volume":"35","author":"Iwamoto","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.xcrm.2026.103058_bib15","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/gt.2011.100","article-title":"Chemical modification and design of anti-miRNA oligonucleotides","volume":"18","author":"Lennox","year":"2011","journal-title":"Gene Ther."},{"key":"10.1016\/j.xcrm.2026.103058_bib16","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1093\/nar\/gkq457","article-title":"Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates","volume":"38","author":"Straarup","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1021\/jm801294h","article-title":"Short Antisense Oligonucleotides with Novel 2\u2032\u22124\u2032 Conformationaly Restricted Nucleoside Analogues Show Improved Potency without Increased Toxicity in Animals","volume":"52","author":"Seth","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xcrm.2026.103058_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/srep30377","article-title":"Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides","volume":"6","author":"Kasuya","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2026.103058_bib19","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1093\/nar\/gkv1210","article-title":"Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts","volume":"44","author":"Burel","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib20","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1093\/nar\/gkf412","article-title":"Antisense properties of tricyclo-DNA","volume":"30","author":"Renneberg","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib21","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1039\/D4MD00394B","article-title":"The bench to bedside journey of tricyclo-DNA antisense oligonucleotides for the treatment of Duchenne muscular dystrophy","volume":"15","author":"Blitek","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.xcrm.2026.103058_bib22","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1021\/ja025557o","article-title":"Efficient RNase H-Directed Cleavage of RNA Promoted by Antisense DNA or 2\u2018F-ANA Constructs Containing Acyclic Nucleotide Inserts","volume":"125","author":"Mangos","year":"2003","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.xcrm.2026.103058_bib23","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1016\/S0960-894X(02)00439-0","article-title":"Oligonucleotides comprised of alternating 2\u2032-Deoxy-2\u2032-fluoro-\u03b2-d-arabinonucleosides and d-2\u2032-deoxyribonucleosides (2\u2032F-ANA\/DNA \u2018Altimers\u2019) induce efficient RNA cleavage mediated by RNase H","volume":"12","author":"Min","year":"2002","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.xcrm.2026.103058_bib24","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1089\/nat.2015.0547","article-title":"Allele-Selective Inhibition of Mutant Huntingtin with 2-Thio- and C5- Triazolylphenyl-Deoxythymidine-Modified Antisense Oligonucleotides","volume":"25","author":"\u00d8stergaard","year":"2015","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.xcrm.2026.103058_bib25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/oli.1.1997.7.187","article-title":"Morpholino antisense oligomers: design, preparation, and properties","volume":"7","author":"Summerton","year":"1997","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"10.1016\/j.xcrm.2026.103058_bib26","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.3390\/molecules14031304","article-title":"Gene Knockdowns in Adult Animals: PPMOs and Vivo-Morpholinos","volume":"14","author":"Moulton","year":"2009","journal-title":"Molecules"},{"key":"10.1016\/j.xcrm.2026.103058_bib27","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1261\/rna.5239604","article-title":"In vivo activity of nuclease-resistant siRNAs","volume":"10","author":"Layzer","year":"2004","journal-title":"RNA"},{"key":"10.1016\/j.xcrm.2026.103058_bib28","doi-asserted-by":"crossref","first-page":"7967","DOI":"10.1021\/bi0343774","article-title":"RNA Interference in Mammalian Cells by Chemically-Modified RNA","volume":"42","author":"Braasch","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.xcrm.2026.103058_bib29","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1021\/jm049167j","article-title":"Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA","volume":"48","author":"Allerson","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xcrm.2026.103058_bib30","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41587-019-0205-0","article-title":"A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system","volume":"37","author":"Alterman","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.103058_bib31","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1089\/jop.2013.0148","article-title":"Novel Hydrophobically Modified Asymmetric RNAi Compounds (sd-rxRNA) Demonstrate Robust Efficacy in the Eye","volume":"29","author":"Byrne","year":"2013","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.xcrm.2026.103058_bib32","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/cbic.201900630","article-title":"Impact of Phosphorothioate Chirality on Double-Stranded siRNAs: A Systematic Evaluation of Stereopure siRNA Designs","volume":"21","author":"Sakamuri","year":"2020","journal-title":"Chembiochem"},{"key":"10.1016\/j.xcrm.2026.103058_bib33","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/nar\/gkab544","article-title":"Chirality matters: stereo-defined phosphorothioate linkages at the termini of small interfering RNAs improve pharmacology in vivo","volume":"50","author":"Jahns","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib34","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41587-024-02336-7","article-title":"Enhancing siRNA efficacy in vivo with extended nucleic acid backbones","volume":"43","author":"Yamada","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.103058_bib35","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkag287","article-title":"Divalent siRNA for prion disease","volume":"54","author":"Gentile","year":"2026","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib36","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1093\/nar\/gkq181","article-title":"Synergistic effects between analogs of DNA and RNA improve the potency of siRNA-mediated gene silencing","volume":"38","author":"Deleavey","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib37","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1126\/science.1258040","article-title":"Structural basis for microRNA targeting","volume":"346","author":"Schirle","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.103058_bib38","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ymthe.2017.12.021","article-title":"Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates","volume":"26","author":"Foster","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.103058_bib39","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.molcel.2019.06.012","article-title":"High-Throughput Analysis Reveals Rules for Target RNA Binding and Cleavage by AGO2","volume":"75","author":"Becker","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.xcrm.2026.103058_bib40","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/nbt1122","article-title":"Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs","volume":"23","author":"Morrissey","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.103058_bib41","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ymthe.2005.11.002","article-title":"Design of Noninflammatory Synthetic siRNA Mediating Potent Gene Silencing <em>in Vivo<\/em>","volume":"13","author":"Judge","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.103058_bib42","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jid.2018.11.007","article-title":"A MicroRNA-29 Mimic (Remlarsen) Represses Extracellular Matrix Expression and Fibroplasia in the Skin","volume":"139","author":"Gallant-Behm","year":"2019","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.xcrm.2026.103058_bib43","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1261\/rna.30706","article-title":"Position-specific chemical modification of siRNAs reduces \u201coff-target\u201d transcript silencing","volume":"12","author":"Jackson","year":"2006","journal-title":"RNA"},{"key":"10.1016\/j.xcrm.2026.103058_bib44","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/nar\/gki193","article-title":"Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality","volume":"33","author":"Elm\u00e9n","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2013.36","article-title":"5' Unlocked Nucleic Acid Modification Improves siRNA Targeting","volume":"2","author":"Snead","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.xcrm.2026.103058_bib46","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1093\/nar\/gkac539","article-title":"From bench to bedside: Improving the clinical safety of GalNAc\u2013siRNA conjugates using seed-pairing destabilization","volume":"50","author":"Schlegel","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib47","doi-asserted-by":"crossref","first-page":"10851","DOI":"10.1093\/nar\/gkab916","article-title":"Overcoming GNA\/RNA base-pairing limitations using isonucleotides improves the pharmacodynamic activity of ESC+ GalNAc-siRNAs","volume":"49","author":"Schlegel","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib48","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf937","article-title":"Modified unlocked nucleic acid (MUNA) mitigates off-target effects of small interfering RNAs","volume":"53","author":"Mori","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib49","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41467-018-02989-4","article-title":"Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity","volume":"9","author":"Janas","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.103058_bib50","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1038\/s41467-022-33061-x","article-title":"Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington\u2019s disease models","volume":"13","author":"Conroy","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.103058_bib51","doi-asserted-by":"crossref","first-page":"12069","DOI":"10.1093\/nar\/gkab1126","article-title":"Structurally constrained phosphonate internucleotide linkage impacts oligonucleotide-enzyme interaction, and modulates siRNA activity and allele specificity","volume":"49","author":"Yamada","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib52","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1261\/rna.789808","article-title":"Strand-specific 5'-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity","volume":"14","author":"Chen","year":"2008","journal-title":"RNA"},{"key":"10.1016\/j.xcrm.2026.103058_bib53","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/nature09039","article-title":"Structural basis for 5'-nucleotide base-specific recognition of guide RNA by human AGO2","volume":"465","author":"Frank","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.103058_bib54","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1126\/science.1221551","article-title":"The Crystal Structure of Human Argonaute2","volume":"336","author":"Schirle","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.103058_bib55","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2011.4","article-title":"siRNA-optimized Modifications for Enhanced In Vivo Activity","volume":"1","author":"Kenski","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.xcrm.2026.103058_bib56","doi-asserted-by":"crossref","first-page":"7581","DOI":"10.1093\/nar\/gkx507","article-title":"5\u0384-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo","volume":"45","author":"Haraszti","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib57","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/cbic.201600130","article-title":"5'-(E)-Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA-GalNAc Conjugates","volume":"17","author":"Parmar","year":"2016","journal-title":"Chembiochem"},{"key":"10.1016\/j.xcrm.2026.103058_bib58","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1093\/nar\/gkw1171","article-title":"siRNA carrying an (E)-vinylphosphonate moiety at the 5\u0384 end of the guide strand augments gene silencing by enhanced binding to human Argonaute-2","volume":"45","author":"Elkayam","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14020260","article-title":"Oligonucleotide Therapeutics: From Discovery and Development to Patentability","volume":"14","author":"Moumn\u00e9","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xcrm.2026.103058_bib60","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","article-title":"Rational design of cationic lipids for siRNA delivery","volume":"28","author":"Semple","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.103058_bib61","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1002\/jps.23672","article-title":"Non-Viral Nanosystems for Gene and Small Interfering RNA Delivery to the Central Nervous System: Formulating the Solution","volume":"102","author":"O\u2019Mahony","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.xcrm.2026.103058_bib62","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav8521","article-title":"Advances in therapeutic applications of extracellular vesicles","volume":"11","author":"Wiklander","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.103058_bib63","doi-asserted-by":"crossref","first-page":"D516","DOI":"10.1093\/nar\/gky1029","article-title":"Vesiclepedia 2019: a compendium of RNA, proteins, lipids and metabolites in extracellular vesicles","volume":"47","author":"Pathan","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib64","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0005-2736(00)00343-6","article-title":"Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures","volume":"1510","author":"Semple","year":"2001","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.xcrm.2026.103058_bib65","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103058_bib66","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.103058_bib67","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jconrel.2016.05.059","article-title":"Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA","volume":"235","author":"Chen","year":"2016","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.xcrm.2026.103058_bib68","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103058_bib69","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1093\/nar\/25.16.3290","article-title":"In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells","volume":"25","author":"Bijsterbosch","year":"1997","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib70","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/nar\/gkw112","article-title":"Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver","volume":"44","author":"Miller","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib71","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/nar\/gky1260","article-title":"Characterization of the interactions of chemically-modified therapeutic nucleic acids with plasma proteins using a fluorescence polarization assay","volume":"47","author":"Gaus","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib72","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1093\/nar\/gkv143","article-title":"Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages","volume":"43","author":"Liang","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib73","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2219523120","article-title":"Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection","volume":"120","author":"Hariharan","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.103058_bib74","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/s41598-024-52667-3","article-title":"Dose-dependent reduction of somatic expansions but not Htt aggregates by di-valent siRNA-mediated silencing of MSH3 in HdhQ111 mice","volume":"14","author":"Driscoll","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2026.103058_bib75","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1111\/epi.18278","article-title":"Durable suppression of seizures in a preclinical model of KCNT1 genetic epilepsy with divalent small interfering RNA","volume":"66","author":"Andreone","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.xcrm.2026.103058_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102799","article-title":"The 2025 Oligo Meeting in Budapest: Highlights of the 21st annual meeting of the oligonucleotide therapeutics society","volume":"37","author":"Godinho","year":"2026","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.xcrm.2026.103058_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24122211","article-title":"Current Aspects of siRNA Bioconjugate for In Vitro and In Vivo Delivery","volume":"24","author":"Tai","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.xcrm.2026.103058_bib78","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1261\/rna.5103703","article-title":"siRNA function in RNAi: a chemical modification analysis","volume":"9","author":"Chiu","year":"2003","journal-title":"RNA"},{"key":"10.1016\/j.xcrm.2026.103058_bib79","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ymthe.2016.10.019","article-title":"Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate","volume":"25","author":"Zimmermann","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.103058_bib80","doi-asserted-by":"crossref","first-page":"10009","DOI":"10.1021\/bi00495a001","article-title":"The asialoglycoprotein receptor: a model for endocytic transport receptors","volume":"29","author":"Spiess","year":"1990","journal-title":"Biochemistry"},{"key":"10.1016\/j.xcrm.2026.103058_bib81","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib82","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1124\/jpet.115.230300","article-title":"Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands Targeting Apolipoprotein B","volume":"357","author":"Watanabe","year":"2016","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.xcrm.2026.103058_bib83","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.103058_bib84","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1002\/anie.201307628","article-title":"Antibody-drug conjugates: an emerging concept in cancer therapy","volume":"53","author":"Chari","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.xcrm.2026.103058_bib85","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1093\/nar\/gkad415","article-title":"Targeted tissue delivery of RNA therapeutics using antibody-oligonucleotide conjugates (AOCs)","volume":"51","author":"Malecova","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib86","doi-asserted-by":"crossref","first-page":"11401","DOI":"10.1093\/nar\/gkac641","article-title":"Enhanced exon skipping and prolonged dystrophin restoration achieved by TfR1-targeted delivery of antisense oligonucleotide using FORCE conjugation in mdx mice","volume":"50","author":"Desjardins","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2016.06.036","article-title":"Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles","volume":"237","author":"Sugo","year":"2016","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.xcrm.2026.103058_bib88","doi-asserted-by":"crossref","first-page":"14868","DOI":"10.1021\/acs.jmedchem.4c00803","article-title":"Structure-Activity Relationship of Antibody-Oligonucleotide Conjugates: Evaluating Bioconjugation Strategies for Antibody-Phosphorodiamidate Morpholino Oligomer Conjugates for Drug Development","volume":"67","author":"Cochran","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xcrm.2026.103058_bib89","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/22143602251324858","article-title":"Antisense RNA therapies for muscular dystrophies","volume":"13","author":"Arechavala-Gomeza","year":"2026","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.xcrm.2026.103058_bib90","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi2245","article-title":"Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier","volume":"16","author":"Barker","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.103058_bib91","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/nbt1339","article-title":"Mechanisms and optimization of in vivo delivery of lipophilic siRNAs","volume":"25","author":"Wolfrum","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.103058_bib92","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/nar\/gky1232","article-title":"Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways","volume":"47","author":"Osborn","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib93","doi-asserted-by":"crossref","first-page":"gkz360","DOI":"10.1093\/nar\/gkz360","article-title":"Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates","volume":"47","author":"\u00d8stergaard","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib94","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/nbt.4297","article-title":"RNAi modulation of placental sFLT1 for the treatment of preeclampsia","volume":"36","author":"Turanov","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.103058_bib95","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.omtn.2022.06.009","article-title":"Chemical optimization of siRNA for safe and efficient silencing of placental sFLT1","volume":"29","author":"Davis","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.xcrm.2026.103058_bib96","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ajhg.2026.01.016","article-title":"Enhanced muscle uptake of chemically optimized miR-23b antisense oligonucleotides as lead compounds for Myotonic Dystrophy type 1","volume":"113","author":"Gonz\u00e1lez-Mart\u00ednez","year":"2026","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.xcrm.2026.103058_bib97","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/nar\/gkab1199","article-title":"Palmitic acid conjugation enhances potency of tricyclo-DNA splice switching oligonucleotides","volume":"50","author":"Relizani","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib98","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1089\/nat.2024.0049","article-title":"Targeting a Novel Site in Exon 51 with Antisense Oligonucleotides Induces Enhanced Exon Skipping in a Mouse Model of Duchenne Muscular Dystrophy","volume":"35","author":"Oppeneer","year":"2025","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.xcrm.2026.103058_bib99","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/nat.2024.0050","article-title":"BMN 351-Induced Exon Skipping and Dystrophin Expression in Skeletal and Cardiac Muscle Lead to Preservation of Motor Function in a Mouse Model of Exon 51 Skip-Amenable Duchenne Muscular Dystrophy","volume":"35","author":"Oppeneer","year":"2025","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.xcrm.2026.103058_bib100","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41587-022-01334-x","article-title":"Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates","volume":"40","author":"Brown","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.103058_bib101","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-026-68993-1","article-title":"Intradermal delivery of lipophilic siRNAs enables prolonged skin retention and sustained gene silencing in a porcine model","volume":"17","author":"Fakih","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.103058_bib102","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41591-020-0787-6","article-title":"STAR particles for enhanced topical drug and vaccine delivery","volume":"26","author":"Tadros","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.103058_bib103","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1021\/bc070060v","article-title":"Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate","volume":"18","author":"Amantana","year":"2007","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.xcrm.2026.103058_bib104","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.omtn.2023.06.022","article-title":"The endosomal escape vehicle platform enhances delivery of oligonucleotides in preclinical models of neuromuscular disorders","volume":"33","author":"Li","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.xcrm.2026.103058_bib105","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1089\/nat.2012.0389","article-title":"Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo","volume":"22","author":"Wong","year":"2012","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.xcrm.2026.103058_bib106","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/mt.2013.31","article-title":"Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection","volume":"21","author":"Wooddell","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.103058_bib107","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/cpdd.318","article-title":"Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers","volume":"6","author":"Schluep","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.xcrm.2026.103058_bib108","first-page":"5","article-title":"The Era of RNA Interference Medicines: The Clinical Landscape of Synthetic Gene Silencing Drugs","volume":"21","author":"Godinho","year":"2019","journal-title":"Sa\u00fade & Tecnologia"},{"key":"10.1016\/j.xcrm.2026.103058_bib109","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/jimd.12251","article-title":"Opportunities and challenges for antisense oligonucleotide therapies","volume":"44","author":"Kuijper","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.xcrm.2026.103058_bib110","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1073\/pnas.75.1.280","article-title":"Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide","volume":"75","author":"Zamecnik","year":"1978","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.103058_bib111","first-page":"84","article-title":"Fomiversen sodium approved to treat CMV retinitis","volume":"39","author":"Piascik","year":"1999","journal-title":"J. Am. Pharm. Assoc."},{"key":"10.1016\/j.xcrm.2026.103058_bib112","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40265-013-0042-2","article-title":"Mipomersen sodium: first global approval","volume":"73","author":"Hair","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.xcrm.2026.103058_bib113","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.103058_bib114","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103058_bib115","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103058_bib116","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","article-title":"Nusinersen: First Global Approval","volume":"77","author":"Hoy","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.xcrm.2026.103058_bib117","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103058_bib118","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103058_bib119","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103058_bib120","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/mus.28372","article-title":"Serious Neurologic Adverse Events in Tofersen Clinical Trials for Amyotrophic Lateral Sclerosis","volume":"71","author":"Lovett","year":"2025","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.xcrm.2026.103058_bib121","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2023.1152318","article-title":"Adverse events in the treatment of spinal muscular atrophy in children and adolescents with nusinersen: A systematic review and meta-analysis","volume":"11","author":"Zhong","year":"2023","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.xcrm.2026.103058_bib122","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/s41591-026-04314-9","article-title":"Antisense oligonucleotide-mediated knockdown therapy in two infants with severe KCNT1 epileptic encephalopathy","volume":"32","author":"Nakayama","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.103058_bib123","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.xcrm.2026.103058_bib124","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.103058_bib125","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jhep.2023.06.013","article-title":"Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial","volume":"79","author":"Kuter","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.xcrm.2026.103058_bib126","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103058_bib127","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/cvr\/cvae109","article-title":"Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial","volume":"120","author":"Wright","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib128","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103058_bib129","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s40120-023-00522-4","article-title":"Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy","volume":"12","author":"Obici","year":"2023","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.xcrm.2026.103058_bib130","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.kint.2022.07.025","article-title":"PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2","volume":"103","author":"Baum","year":"2023","journal-title":"Kidney Int."},{"key":"10.1016\/j.xcrm.2026.103058_bib131","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S2352-3026(23)00037-6","article-title":"Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A\/B): a multicentre, open-label, randomised, phase 3 trial","volume":"10","author":"Srivastava","year":"2023","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.xcrm.2026.103058_bib132","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial","volume":"9","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.xcrm.2026.103058_bib133","doi-asserted-by":"crossref","DOI":"10.3390\/genes16121468","article-title":"Artificial Intelligence-Driven Design of Antisense Oligonucleotides for Precision Medicine in","volume":"16","author":"Leckie","year":"2025","journal-title":"Genes"},{"key":"10.1016\/j.xcrm.2026.103058_bib134","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.744532","volume":"12","author":"Aartsma-Rus","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.xcrm.2026.103058_bib135","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease","volume":"381","author":"Kim","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103058_bib136","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf346","article-title":"The N=1 Collaborative: advancing customized nucleic acid therapies through collaboration and data sharing","volume":"53","author":"Belgrad","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib137","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkag504","article-title":"Addressing the needs of nano-rare patients: the n-Lorem experience","volume":"54","author":"Crooke","year":"2026","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103058_bib138","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41573-024-01059-3","article-title":"The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap","volume":"24","author":"Jonker","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2026.103058_bib140","doi-asserted-by":"crossref","first-page":"104740","DOI":"10.1016\/j.drudis.2026.104740","article-title":"The platform technology approach in the EU regulation of medicines for human use: stakeholder perspectives on its definition and implementation","volume":"31","author":"Oskam","year":"2026","journal-title":"Drug Discov Today"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126004751?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126004751?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:14:35Z","timestamp":1792509275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126004751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":140,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2666379126004751"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.103058","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic oligonucleotides as genetic medicines: The current state and future perspective","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.103058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103058"}}